Clinical Trial Update: Evaluation of the Unstimulated Whole Saliva Flow During and After Radiotherapy, With the Use HcT20 [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating unstimulated saliva flow during and after radiotherapy using HcT20; study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Xerostomia

Drugs mentioned

• HcT20

Snippet

Sponsor: UPECLIN HC FM Botucatu Unesp | Conditions: Abnormalities, Radiation-Induced | Phase 2 | Status: COMPLETED